Corporate Member Update: Gilead-FDA APPROVES TRODELVY®

Corporate Member Update: Gilead-FDA APPROVES TRODELVY®

TRODELVY®
April, 2021

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

To read the full press release, please click here.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members